StreetInsider.com News Articles

JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million

Thu, 12 Jun 2025 08:07:00 -0400

HONG KONG, Jun 12, 2025 - (ACN Newswire) - - KEY HIGHLIGHTS

- Revenue up by 20.7% to HK$782.3 million

- Gross profit increased by 22.4% to HK$413.7 million

- Consolidated profit attributable to equity shareholders grew by 51.2% to HK$197.3 million

- The Board recommends a final dividend of HK11.5 cents per share

- Flagship proprietary brands Ho Chai Kung, Po Chai Pills, and Flying Eagle Woodlok Oil delivered robust growth through effective brand management campaigns

- Concentrated Chinese medicine granules ('CCMG') remained resilient, providing a steady contribution to overall business performance

JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with

JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million

Thu, 12 Jun 2025 08:07:00 -0400

HONG KONG, Jun 12, 2025 - (ACN Newswire) - - KEY HIGHLIGHTS

- Revenue up by 20.7% to HK$782.3 million

- Gross profit increased by 22.4% to HK$413.7 million

- Consolidated profit attributable to equity shareholders grew by 51.2% to HK$197.3 million

- The Board recommends a final dividend of HK11.5 cents per share

- Flagship proprietary brands Ho Chai Kung, Po Chai Pills, and Flying Eagle Woodlok Oil delivered robust growth through effective brand management campaigns

- Concentrated Chinese medicine granules ('CCMG') remained resilient, providing a steady contribution to overall business performance

JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with

JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million

Thu, 12 Jun 2025 08:07:00 -0400

HONG KONG, Jun 12, 2025 - (ACN Newswire) - - KEY HIGHLIGHTS

- Revenue up by 20.7% to HK$782.3 million

- Gross profit increased by 22.4% to HK$413.7 million

- Consolidated profit attributable to equity shareholders grew by 51.2% to HK$197.3 million

- The Board recommends a final dividend of HK11.5 cents per share

- Flagship proprietary brands Ho Chai Kung, Po Chai Pills, and Flying Eagle Woodlok Oil delivered robust growth through effective brand management campaigns

- Concentrated Chinese medicine granules ('CCMG') remained resilient, providing a steady contribution to overall business performance

JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with

JBM Healthcare Delivers Strong FY2025 Annual Results, Net Profit Surged 51.2% to HK$197.3 Million

Thu, 12 Jun 2025 08:07:00 -0400

HONG KONG, Jun 12, 2025 - (ACN Newswire) - - KEY HIGHLIGHTS

- Revenue up by 20.7% to HK$782.3 million

- Gross profit increased by 22.4% to HK$413.7 million

- Consolidated profit attributable to equity shareholders grew by 51.2% to HK$197.3 million

- The Board recommends a final dividend of HK11.5 cents per share

- Flagship proprietary brands Ho Chai Kung, Po Chai Pills, and Flying Eagle Woodlok Oil delivered robust growth through effective brand management campaigns

- Concentrated Chinese medicine granules ('CCMG') remained resilient, providing a steady contribution to overall business performance

JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with

JBM Healthcare Announces FY2025 Interim Results

Tue, 19 Nov 2024 06:51:00 -0400

HONG KONG, Nov 19, 2024 - (ACN Newswire) - - KEY HIGHLIGHTS

- Revenue up by 22.1% to HK$399.0 million

- Gross profit increased by 20.3% to HK$205.9 million

- Consolidated profit attributable to equity shareholders grew by 53.4% to HK$95.9 million

- Interim dividend of HK5.50 cents per share, up by 59.4% year-on-year

- Flagship proprietary brands Ho Chai Kung and Po Chai Pills achieved robust growth through effective integrated sales and marketing strategies

- Concentrated Chinese medicine granules ('CCMG') business displayed solid growth momentum, contributing to operational performance

JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the

JBM Healthcare Announces FY2025 Interim Results

Tue, 19 Nov 2024 06:51:00 -0400

HONG KONG, Nov 19, 2024 - (ACN Newswire) - - KEY HIGHLIGHTS

- Revenue up by 22.1% to HK$399.0 million

- Gross profit increased by 20.3% to HK$205.9 million

- Consolidated profit attributable to equity shareholders grew by 53.4% to HK$95.9 million

- Interim dividend of HK5.50 cents per share, up by 59.4% year-on-year

- Flagship proprietary brands Ho Chai Kung and Po Chai Pills achieved robust growth through effective integrated sales and marketing strategies

- Concentrated Chinese medicine granules ('CCMG') business displayed solid growth momentum, contributing to operational performance

JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the

JBM Healthcare Announces FY2025 Interim Results

Tue, 19 Nov 2024 06:51:00 -0400

HONG KONG, Nov 19, 2024 - (ACN Newswire) - - KEY HIGHLIGHTS

- Revenue up by 22.1% to HK$399.0 million

- Gross profit increased by 20.3% to HK$205.9 million

- Consolidated profit attributable to equity shareholders grew by 53.4% to HK$95.9 million

- Interim dividend of HK5.50 cents per share, up by 59.4% year-on-year

- Flagship proprietary brands Ho Chai Kung and Po Chai Pills achieved robust growth through effective integrated sales and marketing strategies

- Concentrated Chinese medicine granules ('CCMG') business displayed solid growth momentum, contributing to operational performance

JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the

JBM Healthcare Announces FY2025 Interim Results

Tue, 19 Nov 2024 06:51:00 -0400

HONG KONG, Nov 19, 2024 - (ACN Newswire) - - KEY HIGHLIGHTS

- Revenue up by 22.1% to HK$399.0 million

- Gross profit increased by 20.3% to HK$205.9 million

- Consolidated profit attributable to equity shareholders grew by 53.4% to HK$95.9 million

- Interim dividend of HK5.50 cents per share, up by 59.4% year-on-year

- Flagship proprietary brands Ho Chai Kung and Po Chai Pills achieved robust growth through effective integrated sales and marketing strategies

- Concentrated Chinese medicine granules ('CCMG') business displayed solid growth momentum, contributing to operational performance

JBM (Healthcare) Limited ("JBM Healthcare" or the "Company"; Stock Code: 2161, together with its subsidiaries, the

JBM Healthcare Issues Positive Profit Alert

Fri, 01 Nov 2024 00:10:00 -0400

HONG KONG, Nov 1, 2024 - (ACN Newswire) - - JBM (Healthcare) Limited ('JBM Healthcare' or the 'Company'; Stock Code: 2161, together with its subsidiaries, the 'Group'), a leading branded healthcare products marketer and distributor in Hong Kong, has today announced a positive profit alert. Based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended 30 September 2024 and the information currently available to the board of directors of the Company, the Group expects to record an increase in the consolidated profit attributable to shareholders for the six months ended

JBM Healthcare Issues Positive Profit Alert

Fri, 01 Nov 2024 00:10:00 -0400